Stock GILD GILEAD SCIENCES, INC.
Add to a list

Gilead Sciences, Inc. Stock

Stocks

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 16:00:00 2026-06-12 EDT 		5-day change 1st Jan Change
125.59 USD -0.22% Intraday chart for Gilead Sciences, Inc. -2.76% +2.32%
06-09 Lakefront Biotherapeutics Launches 50 Million Euros Share Repurchase Program MT
06-09 Gilead Sciences, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 01:20 PM
Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Gilead Sciences, Inc.

Market Cap 156B 135B 124B 116B 218B 14,821B 221B 1,465B 571B 7,214B 585B 573B 24,978B P/E Ratio 2026 *
-45x
P/E Ratio 2027 * 16.3x
Enterprise Value 165B 143B 132B 123B 231B 15,731B 235B 1,555B 606B 7,657B 621B 608B 26,511B EV / Sales 2026 *
5.43x
EV / Sales 2027 * 4.8x
Free-Float
99.87%
Yield 2026 *
2.58%
Yield 2027 * 2.64%
* Estimated data More valuation ratios

Chart: Gilead Sciences, Inc.

Dynamic Chart

Latest news : Gilead Sciences, Inc.

06-09 Lakefront Biotherapeutics Launches 50 Million Euros Share Repurchase Program MT
06-09 Gilead Sciences, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 01:20 PM
06-09 What Bundibugyo Ebola vaccines and treatments are under development RE
06-09 Wall Street Rises, Risks Remain Zonebourse
06-08 Gilead, Merck HIV Combination Meets Primary Endpoint in Two Phase 3 Trials MT
06-08 Merck, Gilead End Lung Cancer Trial, Report Positive Data From HIV Drug Trials DJ
06-08 Merck, Gilead Discontinue Phase 3 Trial of Trodelvy, Keytruda to Treat Lung Cancer MT
06-08 Gilead Sciences, Inc. And Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, An Oral Once-Weekly HIV Treatment CI
06-08 Merck and Gilead Sciences, Inc. Provides Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study CI
06-08 Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says MT
06-05 The Jobs Report Just Made the Fed's Life Harder Zonebourse
06-05 Keymed Biosciences Receives $257 Million Upfront Payment After Gilead-Ouro Deal Close MT
06-05 To infinity and beyond Zonebourse
More news

Last Transcript: Gilead Sciences, Inc.

Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 01:20 PM
06-09
More transcripts

Analysts' recommendations: Gilead Sciences, Inc.

06-08 Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says MT
05-20 Maxim Upgrades Gilead Sciences to Buy From Hold, Price Target is $165 MT
05-19 Daiwa Securities Adjusts PT on Gilead Sciences to $150 From $161, Maintains Outperform Rating MT
05-11 Gilead's Emvistegrast Readout Unlikely to Move Stock, RBC Says MT
05-11 Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $167 From $170 MT
More recommendations

Press Releases: Gilead Sciences, Inc.

06-12 Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief BU
06-11 National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership BU
06-09 UPC Central Division Revokes Patent Covering Covid-19 Treatment Remdesivir AQ
06-05 Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa BU
06-02 Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC) BU
More press releases

News in other languages: Gilead Sciences, Inc.

06-10 Programme de rachat d'actions pour Lakefront
06-09 Wall Street legt zu, die Risiken bleiben
06-09 Bourse : GSK s'offre Nuvalent pour 10,6 MdsUSD, RIP le SCAF, Orange seul maître à bord en Espagne
06-09 Morning Meeting: La tecnología vuelve a encontrar apoyo
06-09 La tech se remet la tête à l'endroit
More news

Quotes and Performance

1 day-0.22%
1 week-2.76%
Current month-6.58%
1 month-5.61%
3 months-13.38%
6 months+4.31%
Current year+2.32%
More quotes

Course Extremes

1 week 121.39
Extreme 121.39
 130.8
1 month 121.39
Extreme 121.39
 137.2
Current year 116.88
Extreme 116.88
 157.29
1 year 104.46
Extreme 104.46
 157.29
3 years 62.07
Extreme 62.07
 157.29
5 years 57.16
Extreme 57.165
 157.29
10 years 56.56
Extreme 56.56
 157.29
More quotes

Managers and Directors: Gilead Sciences, Inc.

Manager TitleAgeSince
Daniel O'Day CEO
 Chief Executive Officer 61 2019-02-28
Andrew Dickinson DFI
 Director of Finance/CFO 56 2019-10-31
Keeley Wettan CMP
 Compliance Officer - 2025-12-17
Director TitleAgeSince
Kelly Kramer BRD
 Director/Board Member 58 2016-08-18
Jacqueline Barton BRD
 Director/Board Member 73 2017-12-31
Harish Manwani BRD
 Director/Board Member 72 2018-05-08
More insiders

Latest insider transactions

Date Insider Type Main position Quantity % Market Cap.
06-09
Dietmar Berger
Fiscal year

Chief Technology Officer

1,329 0.0001%
06-09
Andrew Dickinson
Fiscal year

Chief Financial Officer

6,933 0.0006%
06-09
Daniel O'Day
Fiscal year

Chief Executive Officer

21,771 0.0018%
Transaction History

Other Pharmaceuticals

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
GILEAD SCIENCES, INC. Stock Gilead Sciences, Inc.
-0.22%-2.76%+14.19%+60.09% 156B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
-2.41%+0.14%+38.28%+154.20% 1,010B
JOHNSON & JOHNSON Stock Johnson & Johnson
+1.07%+3.48%+53.32%+49.85% 580B
ABBVIE INC. Stock AbbVie Inc.
+1.32%+0.22%+19.18%+64.65% 402B
ROCHE HOLDING AG Stock Roche Holding AG
+0.77%0.00%+21.28%+16.70% 330B
NOVARTIS AG Stock Novartis AG
+0.44%+3.48%+25.65%+35.66% 281B
ASTRAZENECA PLC Stock AstraZeneca PLC
-0.85%-2.86%+22.54%+14.67% 280B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+1.66%+1.20%-44.35%-47.35% 197B
AMGEN INC. Stock Amgen Inc.
+0.32%+1.61%+20.32%+60.01% 192B
PFIZER INC. Stock Pfizer Inc.
+0.15%+0.65%+6.81%-34.93% 149B
Average +0.22%+0.82%+17.72%+37.35% 357.83B
Weighted average by Cap. -0.21%+1.02%+26.89%+66.14%
See all sector performances

Financials

2026 *2027 *
Net sales 30.48B 26.32B 24.26B 22.71B 42.55B 2,897B 43.21B 286B 112B 1,410B 114B 112B 4,882B 32.45B 28.03B 25.83B 24.18B 45.31B 3,084B 46.01B 305B 119B 1,501B 122B 119B 5,198B
Net income -3.37B -2.91B -2.68B -2.51B -4.71B -321B -4.78B -31.7B -12.36B -156B -12.66B -12.39B -540B 9.6B 8.29B 7.64B 7.15B 13.41B 913B 13.62B 90.25B 35.19B 444B 36.04B 35.27B 1,538B
Net Debt 9.57B 8.26B 7.62B 7.13B 13.36B 909B 13.57B 89.92B 35.06B 443B 35.91B 35.15B 1,533B -96.43M -83.29M -76.75M -71.84M -135M -9.17B -137M -906M -353M -4.46B -362M -354M -15.45B
* Estimated data More financial data

Company Profile

Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Sector
Pharmaceuticals
Calendar
06-15 - Ex-dividend date - 0.82 USD
More about the company

Quotes

Date Price Change Volume
26-06-12 125.59 $ -0.22% 5,216,092
26-06-11 125.87 $ +3.61% 8,665,609
26-06-10 121.48 $ -3.20% 10,154,248
26-06-09 125.50 $ -2.03% 8,683,055
26-06-08 128.10 $ -0.82% 9,795,952

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

AA
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
125.59USD
Average target price
157.57USD
Spread / Average Target
+25.46%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Stocks
  3. GILD Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition